Last C$0.08 CAD
Change Today 0.00 / 0.00%
Volume 0.0
DMA On Other Exchanges
As of 2:59 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

diamedica inc (DMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - C$1.10
52 Week Low
12/2/14 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAMEDICA INC (DMA)

Related News

No related news articles were found.

diamedica inc (DMA) Related Businessweek News

No Related Businessweek News Found

diamedica inc (DMA) Details

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Founded in 2000

diamedica inc (DMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$276.5K
Vice-President of Research
Total Annual Compensation: C$177.0K
Consulting Chief Medical Officer
Total Annual Compensation: C$11.8K
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

diamedica inc (DMA) Key Developments

DiaMedica Announces Resignation of Mark Robbins as Executive Vice President

DiaMedica Inc. announced that Mark Robbins has resigned his position with the company to pursue other Opportunities. Mark joined DiaMedica as Vice President of Clinical and Regulatory and was named Executive Vice President in July 2014.

Diamedica Inc. Appoints David Gurvey as Vice President of Finance

DiaMedica Inc. announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance. Mr. Gurvey has more than 13 years of experience working with publicly traded and private companies in senior financial roles. Mr. Gurvey is a Chartered Professional Account. Prior to joining DiaMedica, Mr. Gurvey has held Chief Financial Officer positions with both public and private companies. Mr. Gurvey began his career with Ernst & Young Chartered Accountants.

DiaMedica Inc. Announces Restructuring Plans Including Number of Staff Layoffs, Including John Savage as Chief Financial Officer

DiaMedica Inc. announced a company-wide restructuring aimed at preserving cash, reducing operating costs and re-positioning the company going forward. The company's restructuring includes a number of staff layoffs, including John Savage as Chief Financial Officer. DiaMedica plans to continue working with Mr. Savage on a part-time, consultancy basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMA:CN C$0.08 CAD 0.00

DMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAMEDICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at